Prothena (PRTA)
(Delayed Data from NSDQ)
$20.07 USD
-0.32 (-1.57%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $20.06 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRTA 20.07 -0.32(-1.57%)
Will PRTA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRTA
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Other News for PRTA
Prothena (PRTA) Receives a Hold from RBC Capital
Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships
Prothena (PRTA) Receives a Buy from Piper Sandler
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration